Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07052877
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
Overview
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Sponsor
Unknown Organization
Contacts
Alexander Yuile (CONTACT)
alexander.yuile@health.nsw.gov.au
+61 2 94631171
ClinicalTrials.gov
NCT07052877Eligibility
Inclusion
- Able to comply with trial requirements
- ECOG 0-2
- For bevacizumab treatment as per treating physician
- Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
- Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
Exclusion
- Does not fulfill PBS requirements for bevacizumab
- Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
- No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
- Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
- Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
Share your feedback
Help us improve your experience